Over a one-year period, pharma funds have delivered a negative return of 11% to investors. On a long-term though, this thematic category has been among the top performers. Mint’s Abhinav Kaul talked to Aditya Khemka, fund manager at InCred PMS, about the outlook of pharma funds.